Effect of beta-1-blocker, nebivolol, on central aortic pressure and arterial stiffness in patients with essential hypertension

Indian Journal of Pharmacology

Volumn 44, Issue 3, 2012, Pages 407-411

  Soanker, Radhika ^a   Naidu, M U R ^a   Raju, Sree Bhushan ^a   Prasad, A Krishna ^a   Rao, T Ramesh Kumar ^a  

^a NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

arterial stiffness; central aortic pressures; Nebivolol

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NEBIVOLOL;

ADULT; ANKLE BRACHIAL INDEX; ANTIHYPERTENSIVE ACTIVITY; AORTA PRESSURE; ARTERIAL STIFFNESS; ARTICLE; AUGMENTATION INDEX; CAROTID ARTERY PULSE; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FEMALE; HEART RATE; HUMAN; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; OPEN STUDY; OUTCOME ASSESSMENT; PULSE WAVE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 84861905807     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.96349     Document Type: Article

References (22)

1. George T, Ajit SM. Atenolol in Hypertension. J Assoc Physicians India 2009;57 Suppl:S22-5.
2. JNC 7 Express: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, U.S.Department Health and Human Services, NIH, NHLBI.
3. Sabovic M, Safar ME, Blacher J. Is there any additional prognostic valueof central blood pressure wave forms beyond peripheral blood pressure. Curr Pharm Des 2009;15:254-66.
4. McEniery CM. Antihypertensive drugs and central blood pressure. Curr Hypertens Rep 2009;11:253-9.
5. Agabiti Rosei E, Rizzoni D. Metabolic profile of nebivolol, a beta adrenoceptor antagonist with unique characteristics. Drugs 2007;67:1097-107.
6. Dhakam Z, Yasmin, McEniery CM, Burton T, Brown MJ, Wilkinson IB. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens 2008;26:351-6.
7. Mahmud A, Feely J. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens 2008;21:663-7.
8. Weiss RJ, Weber MA, Carr AA, Sullivan WA. A randomized, double-blind placebo controlled parallel-group study to assess the efficacy and safety of nebivolol, novel blocker in patients with mild to moderate hypertension. J Clin Hypertens 2007;9:667-76.
9. Saunders E, Smith WB, DeSalvo KB, Sullivan WA. The efficacy and tolerability of nebivolol in hypertensive African American patients. J Clin Hypertens 2007;9:866-75.
10. Agabiti-Rosei E, Porteri E, Rizzoni D. Arterial stiffness, hypertension, and rational use of nebivolol. Vasc Health Risk Manag 2009;5:353-60.
11. Cockcroft J. A review of the safety and efficacy of nebivolol in the mild hypertensive patient. Vasc Health Risk Manag 2007;3:909-17.
12. Doumas M, Tsakiris A, Douma S, Grigorakis A, Papadopoulos A, Hounta A, et al. Beneficial effects of switching from ?-blockers to nebivolol on the erectile function of hypertensive patients. Asian J A ndrol 2006;8:177-82.
13. Chen CH, Ting CT, Lin SJ, Hsu TL, Yin FC, Siu CO, et al. Different effects of fosinopril and atenolol on wave reflection in hypertensive patients. Hypertension 1995;25:1034-41.
14. Dhakam Z, McEniery CM, Yasmin, Cockcroft JR, Brown MJ, Wilkinson IB. Atenolol and eprosartan: Differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens 2006;19:214-9.
15. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. Differential impact of blood pressure lowering drugs on central aortic pressure and clinical outcomes. Principal Results of the Conduit Artery Function Evaluation (CAFE) Study. Circulation 2006;113:1213-25.
16. Burnier M, Bullani R, Vogt B. Beta-blockers for the treatment of essential hypertension: What are the arguments against their use as first line therapy? Curr Hypertens Rev 2007;3:15-20.
17. Weber T, Auer J, O'Rourke MF, Kvas E, Lassnig E, Berent R, et al. Arterial stiffness, wave reflections, and the risk of coronary artery disease. Circulation 2004;109:184-9.
18. Safar H, Mourad JJ, Safar M, Blacher J. Aortic pulse wave velocity, an independent marker of cardiovascular risk. Arch Mal Coeur Vaiss 2002;95:1215-8.
19. Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, et al. Prognostic valueof aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006;113:664-70.
20. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001;37:1236-41.
21. McEniery CM, Schmitt M, Qasem A, Webb DJ, Avolio AP, Wilkinson IB, et al. Nebivolol increases arterial distensibility in vivo. Hypertension 2004;44: 305-10.
22. Lacourcière Y, Arnott W. Placebo-controlled comparison of the effects of nebivolol and low-dose hydrochlorthiazide as monotherapies and in combination on blood pressure and lipid profile in hypertensive patients. J Hum Hypertens 1994;8:283-8.